Skymount Medical received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a clinical trial of its oral treatments for mild-to-moderate Covid-19.
The double-blind human trial will analyse the potential impact of a two-drug combination and a single antiviral drug versus placebo on Covid-19 symptom severity and duration.
Go deeper with GlobalData
Discovered using the Louisiana State University (LSU)-developed DeepDrug artificial intelligence platform, the two-drug combo consists of a cancer therapy and an anti-parasitic agent.
Both the therapies have previously obtained approval from the US Food and Drug Administration (FDA).
Intended to address the viral load, as well as the inflammatory aspects of Covid-19, the treatment demonstrated to reduce SARS-CoV-2 viral load in cell and animal studies.
It was also found to have no negative side effects.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTo commence the trial, the company will seek necessary UK Ethics Committee approval and identify appropriate study centres.
The trial is anticipated to enrol 150 subjects with mild-to-moderate Covid-19 in the UK trial.
Skymount Medical chief medical and scientific officer Dr Kishor Wasan said: “There are currently limited approved oral medication options to alleviate Covid-19 symptoms in adult patients who are not hospitalised, and the drug combination or single drug would be administered at the first sign of infection, reducing the amount and duration of symptoms, and allowing patients to avoid hospitalisation.
“With our drug combination already in a human pilot study in the United States, we are pleased to expand the reach of this combination therapy internationally.”
Utilising various crucial components, the DeepDrug platform offers a compound and formula generation expertise that significantly lowers the time and expenses linked to standard drug discovery.
